Cogswell, Petrice M. http://orcid.org/0000-0002-8128-4476
Lundt, Emily S. http://orcid.org/0000-0002-4754-8642
Therneau, Terry M.
Mester, Carly T. http://orcid.org/0000-0002-5863-946X
Wiste, Heather J.
Graff-Radford, Jonathan
Schwarz, Christopher G. http://orcid.org/0000-0002-1466-8357
Senjem, Matthew L. http://orcid.org/0000-0001-9308-9275
Gunter, Jeffrey L.
Reid, Robert I. http://orcid.org/0000-0003-2391-8650
Przybelski, Scott A.
Knopman, David S. http://orcid.org/0000-0002-6544-066X
Vemuri, Prashanthi http://orcid.org/0000-0003-4286-0589
Petersen, Ronald C. http://orcid.org/0000-0002-8178-6601
Jack, Clifford R. Jr http://orcid.org/0000-0001-7916-622X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01 AG006786, P50 AG016574, R37 AG011378, RO1 AG041851, R01 NS097495, R01 AG056366)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 30 August 2022
Accepted: 15 May 2023
First Online: 29 May 2023
Competing interests
: P.M.C, E.S.L., T.M.T., C.T.M., H.J.W, J.L.G., R.I.R., and S.A.P. have no disclosures. J.G.R. serves as an assistant editor for Neurology and receives research support from the NIH. C.G.S. receives research support from the NIH. M.L.S. holds stock in medical-related companies, unrelated to the current work: Align Technology, Inc., LHC Group, Inc., Medtronic, Inc., Mesa Laboratories, Inc., Natus Medical Inc., and Varex Imaging Corporation. He has also owned stock in these medical-related companies within the past three years, unrelated to the current work: CRISPR Therapeutics, Gilead Sciences, Inc., Globus Medical Inc., Inovio Biomedical Corp., Ionis Pharmaceuticals, Johnson & Johnson, Medtronic, Inc., Oncothyreon, Inc., Parexel International Corporation. D.S.K. served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety Monitoring Board for a tau therapeutic for Biogen but receives no personal compensation. He was a site investigator in the Biogen aducanumab trials. He is an investigator in a clinical trial sponsored by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock, Roche, and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH. P.V. received speaker fees from Miller Medical Communications, Inc. and receives research support from the NIH. R.C.P. serves as a consultant for Roche Inc., Merck Inc., and Biogen, Inc. He serves on the Data Safety Monitoring Board for Genentech, Inc and receives a royalty from Oxford University Press and UpToDate. C.R.J. serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic.